Paraneoplastic Autoimmune Dermatological Conditions

Paraneoplastic autoimmune dermatological conditions represent a heterogeneous group of skin and mucosal disorders that arise in the context of an underlying neoplasm. These conditions are not caused by direct tumour invasion but by immune responses directed against antigens shared by the tumour and cutaneous structures. Clinical manifestations range from blistering and lichenoid eruptions, as seen in paraneoplastic pemphigus, to distinctive keratotic and pigmentary changes, such as those of acrokeratosis paraneoplastica. Pathogenesis involves both humoral and cellular mechanisms, with autoantibody production against desmosomal and plakin proteins alongside T-cell–mediated epidermal damage. Early recognition of cutaneous signs can prompt the diagnosis of an occult malignancy, while management demands a multidisciplinary approach involving dermatologists, oncologists and immunologists. Therapeutic strategies aim to control the underlying tumour, suppress aberrant immune activity and alleviate skin symptoms through systemic corticosteroids, immunomodulators, biologics and, in selected cases, targeted agents. Despite advances in diagnostics and therapeutics, prognosis remains guarded owing to the severity of skin involvement and complications from the associated neoplasm or immunosuppressive therapy.

Research from Nature Portfolio

A retrospective study of chronic lymphocytic leukaemia–associated paraneoplastic pemphigus identified fludarabine-based chemotherapy as a potential trigger for the autoimmune eruption. Patients developed mucocutaneous lesions a median of three years after CLL diagnosis, with bronchiolar complications contributing to high mortality. Combined regimens incorporating rituximab, high-dose corticosteroids, intravenous immunoglobulins and fresh frozen plasma achieved partial remission in most cases, while early use of a Bruton’s tyrosine kinase inhibitor showed promise in reducing disease severity. These findings highlight the need for vigilant dermatological monitoring in haematological malignancies and suggest personalised immunochemotherapy strategies may improve outcomes.

Paraneoplastic Autoimmune Dermatological Conditions publication trend

The graph below shows the total number of articles in paraneoplastic autoimmune dermatological conditions across all publications each year (not limited to Nature Index journals).

Technical terms

Paraneoplastic: clinical phenomena resulting from immune responses to a neoplasm rather than direct tumour invasion.

Autoantibody: an immunoglobulin produced by the host that mistakenly targets self-antigens.

Pemphigus: a group of rare autoimmune blistering disorders affecting the skin and mucous membranes.

Acrokeratosis paraneoplastica (Bazex syndrome): a paraneoplastic dermatosis characterised by psoriasiform acral keratotic lesions, often preceding cancer diagnosis.

Thalidomide: an immunomodulatory and anti-angiogenic agent used off-label in refractory autoimmune disorders.

References

1. Paraneoplastic cutaneous manifestations: concepts and updates*. Anais Brasileiros de Dermatologia (2013).
2. Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy. International Journal of Molecular Sciences (2017).
3. Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies. Scientific Reports (2020).
4. Bazex Syndrome (Acrokeratosis Paraneoplastica): A Narrative Review of Pathogenesis, Clinical Manifestations, and Therapeutic Approaches. Cureus (2023).
5. Thalidomide as a potential adjuvant treatment for paraneoplastic pemphigus: A single‐center experience. Dermatologic Therapy (2020).
6. Thymoma-Associated Paraneoplastic Autoimmune Multiorgan Syndrome—From Pemphigus to Lichenoid Dermatitis. Frontiers in Immunology (2019).